Please Wait
Applying Filters...
menu
    • menu
    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Ramucirumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 10Cyramza

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Cyramza

    Ramucirumab

    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 1,033

    2019 Revenue in Millions : 925

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Cyramza

    Ramucirumab

    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 1,033

    2020 Revenue in Millions : 1,033

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Cyramza

    Ramucirumab

    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 971

    2021 Revenue in Millions : 1,033

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Cyramza

    Ramucirumab

    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 975

    2022 Revenue in Millions : 971

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Cyramza

    Ramucirumab

    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 973

    2023 Revenue in Millions : 975

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Cyramza

    Ramucirumab

    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2015 Revenue in Millions : 76

    2014 Revenue in Millions : 384

    Growth (%) : 405%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Cyramza

    Ramucirumab

    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2016 Revenue in Millions : 614

    2015 Revenue in Millions : 384

    Growth (%) : 60

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Cyramza

    Ramucirumab

    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 758

    2016 Revenue in Millions : 614

    Growth (%) : 23

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Cyramza

    Ramucirumab

    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 821

    2017 Revenue in Millions : 758

    Growth (%) : 8%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Cyramza

    Ramucirumab

    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Brand Name : Cyramza

    U.S.A
    arrow
    BIO Asia-Taiwan
    Not Confirmed

    Eli Lilly

    Ramucirumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 925

    2018 Revenue in Millions : 821

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF